With just a few months to go before Eli Lilly expects to launch its own oral GLP-1 obesity drug, Novo Nordisk is making the ...

The new chairman of the CDC's Advisory Committee on Immunization Practices, Kirk Milhoan, M.D., Ph.D., recently took to the ...

Plotting a challenge to Regeneron’s blockbuster Eylea, Ocular Therapeutix has hired “a key architect” of its rival’s launch ...

GLP-1 giant Eli Lilly has once again taken to the medium of short film to deliver an important message about obesity. | GLP-1 ...

ST Pharm has struck a deal with an undisclosed U.S.-based biotech to produce active pharmaceutical ingredients (APIs) for an ...

In 2025's third quarter, multiple large vaccine developers, including Pfizer and GSK, saw vaccine sales tick up globally ...

As Sandoz looks to address the “biosimilar void” created by the scores of lucrative drugs going off patent in the next decade ...

Despite falling short in its recent bid to snatch Avadel from Alkermes, Lundbeck is signaling to investors that it’s not ...

While the threat of U.S. import tariffs prompted a surge in drug production last year, that output is slated to slow across multiple geographies in 2026. | While the threat of U.S. import tariffs ...

After U.S. President Donald Trump took the stage at the World Economic Forum this week to tout the supposed success of his ...

Amid a viral social media trend glorifying the halcyon days of 2016, Novo Nordisk has gone back an extra decade to find ...

With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...